ARTICLE | Clinical News
Intracerebroventricular valproate: Ph I/II ADDRESS started
March 16, 2017 4:11 PM UTC
Cerebral Therapeutics began the Australian Phase I/II ADDRESS trial to evaluate intracerebroventricular valproate delivered via the implantable Prometra II drug pump system in 12 patients. The double-...
BCIQ Target Profiles